With more than 4,000 attendees, 630 speakers, and 300 exhibitors, SCOPE 2026 reinforced its position as a bellwether for clinical innovation. This year’s event showed a notable presence of technology vendors focused on providing eClinical solutions, including risk-based quality management (RBQM), randomization and trial supply management (RTSM), eSourcing, and clinical trial supply chain and logistics solutions. The central theme was particularly noteworthy: AI adoption in clinical research has matured and digital protocols are now the backbone enabling it. SCOPE 2026 stood out not only for the high level of participation but also for a distinct shift in tone. The industry is finally advancing beyond conceptual discussions about AI, data integration, and patient-centricity toward actual execution.

Through the various presentations, panel discussions, and plenary keynote sessions, five major themes emerged that include patient centricity, AI taking center stage in clinical trials, digital protocols for clinical trial execution, connected clinical data systems, and modernized site enablement. Overall, SCOPE 2026 underscored a pivotal industry shift indicating that AI is now purposeful, patient‑centric and utilizes sound digital protocols.

• Why are connected data, agentic AI, and flexible trial execution models gaining momentum and driving growth?
• How is clinical research accelerating toward a future defined by smarter workflows, reduced burden, and truly adaptive trial design aligned with real‑world needs?
• What are the emerging growth opportunities influencing major themes covered in SCOPE 2026?